Aankondiging • Sep 19

NKGen Biotech Provides Compliance Update with Nasdaq Listing Rules

As previously disclosed, on March 11, 2024, NKGen Biotech, Inc. (the ‘Company’) received written notice (the ‘MVLS Notice’) from the Listing Qualifications Staff (the ‘Staff’) of the Nasdaq Stock Market, LLC (‘Nasdaq’) notifying the Company that for the last 30 consecutive business days prior to the date of the MVLS Notice, the Company’s Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the ‘MVLS Requirement’). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until September 9, 2024 (‘Compliance Deadlines’), to regain compliance with the MVLS Requirement. If, at any time before September 9, 2024, the market value of the Company’s common stock (calculated in accordance with Nasdaq rules) closed at $50 million or more for a minimum of ten consecutive business days, Nasdaq would provide written confirmation to the Company and close the matter. The Company was unable to regain compliance with the MVLS Requirement by the Compliance Deadline. As previously disclosed, on August 20, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (together with the MVLS Requirement, the ‘Rules’) because it had not timely filed its Form 10-Q (the ‘10-Q’) with the U.S. Securities and Exchange Commission (the ‘SEC’) on or before August 19, 2024, the extended period provided for the filing under Rule 12b-25(b) of the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’). On September 10, 2024, the Company received a new notification letter from Nasdaq (the ‘Delisting Notice’) notifying the Company that, as a result of the Company’s failure to regain compliance with the Rules by the Compliance Deadline, Nasdaq has determined to delist the Company’s common stock from the Nasdaq Global Market. Unless the Company submits an appeal and a hearing request appealing the delisting determination to Nasdaq by no later than 4:00pm Eastern Time on September 17, 2024 (the ‘Appeal Deadline’), the Company’s common stock will be suspended at the opening of business on September 19, 2024 and will be delisted from the Nasdaq Global Market. On September 12, 2024, the Company filed the 10-Q with the SEC, thereby regaining compliance with Nasdaq Listing Rule 5250(c)(1). The Company currently intends to appeal Nasdaq’s determination to a hearings panel (the ‘Hearings Panel’), as well as a request to stay the suspension of its common stock pending the hearing date, pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series by no later than the Appeal Deadline. Hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request. A request for a hearing regarding a delinquent filing will stay the suspension of the Company’s securities only for a period of 15 days from the date of the request, provided that when the Company requests a hearing, it may also request an additional stay of the suspension, through the date of the hearing. The Company intends to request the additional stay of the suspension, and such request must include an explanation of why an extended stay is appropriate. The Hearings Panel will review the request for an extended stay and notify the Company of its conclusion as soon as is practicable but, in any event, no later than 15 calendar days following the deadline to request the hearing. No assurances can be provided that the Nasdaq will grant a stay of the suspension of its common stock beyond the 15 day automatic stay period. Furthermore, even if Nasdaq extends the stay, no assurances can be provided that the Company will obtain a favorable decision from the Hearings Panel, and/or that the Company will be able to regain or maintain compliance with the Nasdaq listing rules and continue the listing of its common stock on the Nasdaq Global Market. If the Company’s securities are delisted from Nasdaq, it could be more difficult to buy or sell the Company’s common stock and warrants or to obtain accurate quotations, and the price of the Company’s common stock and warrants could suffer a material decline. Delisting could also impair the Company’s ability to raise capital and/or trigger defaults and penalties under outstanding agreements or securities of the Company. On September 11, 2024, the Company, received written notice (the ‘MVPHS Notice’) from the Nasdaq notifying the Company that, based on the market value of publicly held shares for the previous 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(C), which requires the Company’s listed securities to maintain a minimum market value of publicly held shares of $15,000,000 (the ‘MVPHS Requirement’). The MVPHS Notice has no immediate effect on the listing of the Company's securities on Nasdaq. The Company intends to monitor the market value of the Company's listed securities and may, if appropriate, consider available options to regain compliance with the MVPHS Requirement. Under Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days (or until March 10, 2025) to regain compliance with the MVPHS Requirement. To regain compliance during this 180-day compliance period, the minimum market value of publicly held shares must close at $15,000,000 or more for a minimum of 10 consecutive business days. In the event that the Company does not regain compliance with the MVPHS Requirement prior to the expiration of the 180-day compliance period, the Company will receive written notification from Nasdaq that the Company's securities are subject to delisting. At that time, the Company may appeal the relevant delisting determination to the Hearings Panel pursuant to the procedures set in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the Hearings Panel, that such appeal would be successful.

Biotechs Groei van de industrie	17.04%
Inkomstengroei	n/a
Rendement op eigen vermogen	n/a
Nettomarge	n/a
Laatste winstupdate	31 Mar 2025

Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 25	-24	15	9
31 Dec 24	-44	16	11
30 Sep 24	-48	18	13
30 Jun 24	-88	17	14
31 Mar 24	-80	15	15
31 Dec 23	-83	14	16
30 Sep 23	-56	11	16
30 Jun 23	-30	10	16
31 Mar 23	-29	9	16
31 Dec 22	-27	8	17
31 Dec 21	-23	8	15

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/08/24 13:50
Aandelenkoers aan het einde van de dag	2026/08/19 00:00
Inkomsten	2025/03/31
Jaarlijkse inkomsten	2024/12/31

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

NKGen Biotech Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

NKGen Biotech Showcases Troculeucel Data and China Opportunities at 2026 BIOCHINA Forum

NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’S Disease Program

NKGen Biotech, Inc. Presents Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia

Nkgen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’S Disease

NKGen Biotech, Inc. Appoints Bruce L. Miller to Scientific Advisory Board

NKGen Biotech, Inc. to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum

NKGen Biotech, Inc. Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025

Nkgen Biotech, Inc. Receives Fda Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

The Nasdaq Stock Market to Delist the Common Stock of NKGen Biotech

Nkgen Biotech, Inc. Announces the Administration of the First Dose of Troculeucel

Nkgen Biotech Announces International and U.S. Expansion of Phase 1/2A Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida

NKGen Biotech, Inc. announced delayed 10-Q filing

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

NKGen Biotech, Inc. announced delayed annual 10-K filing

NKGen Biotech, Inc. announced that it has received $5 million in funding

NKGen Biotech, Inc.(OTCPK:NKGN) dropped from S&P TMI Index

NKGen Biotech, Inc.(OTCPK:NKGN) dropped from NASDAQ Composite Index

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech, Inc. Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech, Inc. Appoints Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

NKGen Biotech, Inc. Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease

NKGen Biotech, Inc. Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

NKGen Biotech, Inc. announced delayed 10-Q filing

NKGen Biotech Inc. Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

The Nasdaq Stock Market Notifies NKGen Biotech That it Withdraws the Staff Deficiency Letter

NKGen Biotech, Inc. Announces Board and Committee Elections

NKGen Biotech Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

NKGen Biotech Provides Compliance Update with Nasdaq Listing Rules

NKGen Biotech, Inc. Announces Pierre Gagnon as Chief Operating Officer and as an Officer of the Company

NKGen Biotech Receives Notification from Nasdaq Related to Delayed Quarterly Report

NKGen Biotech, Inc. announced delayed 10-Q filing

NKGen Biotech, Inc Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference

NKGen Biotech, Inc., Annual General Meeting, Aug 28, 2024

NKGen Biotech, Inc. Elects Dr. Marco Gottardis as Class I Director, Audit Committee, Compensation Committee and N&Cg Committee

NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech, Inc.’s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer’s Disease

NKGen Biotech, Inc. announced delayed 10-Q filing

NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP

NKGen Biotech, Inc. announced delayed annual 10-K filing

NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease At the Tau2024 Global Conference

NKGen Biotech Receives Non-Compliance Notice from Nasdaq Regarding Market Value of Listed Securities Requirement

New major risk - Share price stability

NKGen Biotech Receives a Written Notice from the Nasdaq Stock Market

NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee

High number of new and inexperienced directors

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease

NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease

Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease

No independent directors

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

Bedrijfsanalyse en status van financiële gegevens

Gegevensbronnen

Analysemodel en Snowflake

Industrie en sector

Bronnen van analisten